keyword
MENU ▼
Read by QxMD icon Read
search

Contrave

keyword
https://www.readbyqxmd.com/read/28604472/perioperative-pain-management-of-a-patient-taking-naltrexone-hcl-bupropion-hcl-contrave-a-case-report
#1
Allen Ninh, Sang Kim, Andrew Goldberg
A 42-year-old obese woman (body mass index = 30.2 kg/m) presented for urgent anterior cervical diskectomy and fusion. She had been taking oral naltrexone-bupropion extended-release (Contrave, Orexigen Therapeutics Inc, La Jolla, CA) for the past 6 months and continued using it until 12 hours preoperatively. Despite discontinuation of this medication, and employing an intraoperative and postoperative multimodal analgesia strategy, immediate pain control was inadequately achieved. Patients taking opioid antagonists who present for surgery pose unique challenges to the anesthesiologist and require extensive preoperative interdisciplinary discussions and planning for pain control throughout the perioperative period...
June 8, 2017: A & A Case Reports
https://www.readbyqxmd.com/read/28162685/-434-considerations-for-perioperative-contrave-naltrexone-hcl-bupropion-hcl-administration
#2
M Shehebar, Y Khelemsky
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28130024/acute-generalized-erythrodermic-pustular-psoriasis-associated-with-bupropion-naltrexone-contrave-%C3%A2
#3
Priyanka A Singh, Kerry P Cassel, Ronald M Moscati, David Eckersley
BACKGROUND: We report a case of erythrodermic pustular psoriasis associated with initiation of bupropion/naltrexone (Contrave®; Orexigen Therapeutics, La Jolla, CA) in a patient with no history of psoriasis. CASE REPORT: A 55-year-old woman was transferred to our tertiary medical center from a community hospital for possible Stevens-Johnson syndrome 3 weeks after initiation of bupropion/naltrexone. The patient was admitted to the burn unit for wound treatment and hydration...
April 2017: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/27988274/improving-efficacy-of-the-adjustable-gastric-band-studies-of-the-use-of-adjuvant-approaches-in-a-rodent-model
#4
Aneta Stefanidis, Christine Cheuk Man Lee, Wendy A Brown, Brian J Oldfield
BACKGROUND: The laparoscopic adjustable gastric band (AGB) has been effective in reducing excess weight by approximately 50% for at least 16 years. However, as with all weight loss approaches, reduction in weight resulting from bariatric surgery is associated with a compensatory reduction in energy expenditure, which may confound and limit weight loss. Adjuvant therapies that reduce food intake and increase energy expenditure may be used to improve weight loss outcomes by ameliorating, or even reversing, this reduction in energy expenditure...
February 2017: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
https://www.readbyqxmd.com/read/27802209/comparative-study-between-microvascular-tone-regulation-and-rheological-properties-of-blood-in-patients-with-type-2-diabetes-mellitus
#5
N Antonova, K Tsiberkin, S Podtaev, V Paskova, I Velcheva, N Chaushev
The aim of the study is to investigate the changes of the skin blood flow responses to cold stress in patients with diabetes mellitus type 2 through wavelet analysis of the peripheral skin temperature oscillations and to estimate their relationship with the blood viscosity values. The amplitudes of the skin temperature pulsations (ASTP) were monitored by "Microtest" device ("FM-Diagnostics", Russia); the whole blood viscosity and the shear stresses were measured by Contraves LS30 viscometer (Switzerland) at a steady flow in 9 healthy subjects and in 30 patients with type 2 diabetes mellitus...
2016: Clinical Hemorheology and Microcirculation
https://www.readbyqxmd.com/read/27773782/obesity-current-and-potential-pharmacotherapeutics-and-targets
#6
REVIEW
Vidya Narayanaswami, Linda P Dwoskin
Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders. Pharmacotherapeutic strategies to treat obesity are urgently needed. Research over the past two decades has increased substantially our knowledge of central and peripheral mechanisms underlying homeostatic energy balance. Homeostatic mechanisms involve multiple components including neuronal circuits, some originating in hypothalamus and brain stem, as well as peripherally-derived satiety, hunger and adiposity signals that modulate neural activity and regulate eating behavior...
February 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27014934/influence-of-magnetostimulation-therapy-on-rheological-properties-of-blood-in-neurological-patients
#7
Anna Marcinkowska-Gapińska, Piotr Kowal
The aim of the study is to test the influence of in vivo magnetostimulation on the rheological properties of blood in neurological patients. Blood circulation in the body depends both on the mechanical properties of the circulatory system and on the physical and physicochemical properties of blood. The main factors influencing the rheological properties of blood are as follows: hematocrit, plasma viscosity, whole-blood viscosity, red cells aggregability, deformability, and the ability of red cells to orient in the flow...
2016: Electromagnetic Biology and Medicine
https://www.readbyqxmd.com/read/26957883/naltrexone-bupropion-er-contrave-newly-approved-treatment-option-for-chronic-weight-management-in-obese-adults
#8
Matthew M Sherman, Sinziana Ungureanu, Jose A Rey
Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults.
March 2016: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/26679384/naltrexone-bupropion-for-the-treatment-of-obesity-and-obesity-with-type-2-diabetes
#9
REVIEW
Caroline M Apovian
Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification. Its safety and efficacy were assessed in four randomized, double-blind, placebo-controlled, 56-week Phase III clinical trials in 4536 adult subjects: COR-1, COR-II, COR-BMOD and COR-DM. All four studies demonstrated statistically significant and clinically meaningful weight loss following up to 52 weeks of treatment with naltrexone/bupropion compared with placebo...
March 2016: Future Cardiology
https://www.readbyqxmd.com/read/26648466/approaches-for-the-development-of-drugs-for-treatment-of-obesity-and-metabolic-syndrome
#10
REVIEW
Maksim L Maksimov, Andrey A Svistunov, Vadim V Tarasov, Vladimir N Chubarev, Marco Ávila-Rodriguez, George E Barreto, Olga V Dralova, Gjumrakch Aliev
Obesity and metabolic syndrome (MS) are risk factors for diabetes, cancer, some cardiovascular and musculoskeletal diseases. Pharmacotherapy should be used when the body mass index (BMI) exceeds 30 kg/m² or 27 kg/m² with comorbidity. Efficacy and safety of pharmacotherapy depend on the mechanism of action of drugs. In this context, drugs affecting the central and peripheral mediator systems such as cannabinoid receptor antagonists (Rimonabant), neuronal reuptake inhibitor of NE and 5 HT (Sibutramine), neuronal reuptake inhibitor of NE 5-HT DA (Tesofensine), agonist of 5 HT 2C receptors (Lorcaserin) have a high risk of side effects on the central nervous and cardiovascular systems when used for a long period...
2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/26313898/obesity-medications-what-does-the-future-look-like
#11
REVIEW
W Scott Butsch
PURPOSE OF REVIEW: Lifestyle modification remains the mainstay of treatment for obesity despite the lack of substantial long-term efficacy. For many who do not respond to lifestyle therapy and are not candidates for weight loss surgery, pharmacotherapy is a viable treatment option. Advances in understanding mechanisms of appetite control, nutrient sensing, and energy expenditure have not only helped shape current drug development but have also changed the way in which antiobesity medications are prescribed...
October 2015: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/26222044/patient-reported-quality-of-life-in-a-randomized-placebo-controlled-trial-of-naltrexone-bupropion-for-obesity
#12
RANDOMIZED CONTROLLED TRIAL
R L Kolotkin, S Chen, P Klassen, K Gilder, F L Greenway
Weight loss is associated with improved quality of life in some, but not all, weight loss trials. We evaluated changes at 56 weeks in quality of life, measured by the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire, in a pooled analysis of patient-level data from four randomized controlled Phase 3 studies of naltrexone/bupropion (NB32 or Contrave®). The total number of subjects was 3362 (NB32 = 2043; placebo = 1319; mean body mass index = 36.3 kg m(2); mean age = 46). Improvements in IWQOL-Lite Total Score were greater in subjects treated with NB32 (11...
October 2015: Clinical Obesity
https://www.readbyqxmd.com/read/26105116/naltrexone-er-bupropion-er-a-review-in-obesity-management
#13
REVIEW
Sarah L Greig, Gillian M Keating
Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave(®), Mysimba(™)) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥ 30 kg/m(2) (i.e. obese) or a BMI of ≥ 27 kg/m(2) (i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥ 5 and ≥ 10%...
July 2015: Drugs
https://www.readbyqxmd.com/read/25884863/naltrexone-buproprion-contrave-for-weight-loss
#14
Jessica Early, Jean Suzin Whitten
No abstract text is available yet for this article.
April 15, 2015: American Family Physician
https://www.readbyqxmd.com/read/25661549/new-medications-for-treatment-of-obesity-metabolic-and-cardiovascular-effects
#15
REVIEW
Andrea Pucci, Nicholas Finer
The management of obesity remains a major challenge. Dietary therapy often fails, whereas bariatric surgery, although successful, is demanding and applicable to a limited number of patients. Drug therapy has had many setbacks over the past 20 years because of serious adverse effects; however, several new drugs for the treatment of obesity are either licensed in some parts of the world, submitted for registration, or completing phase III trials. These include combinations (at low dose) of existing drugs, e.g...
February 2015: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/25395816/pharmaceutical-approval-update
#16
Kunj Gohil
Naltrexone/bupropion (Contrave) for weight management; pembrolizumab (Keytruda) for melanoma; dolutegravir/abacavir/lamivudine (Triumeq) for HIV-1; and immune globulin infusion 10% (human) with recombinant human hyaluronidase (Hyqvia) for primary immunodeficiency.
November 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/25372849/contrave-a-combination-of-bupropion-and-naltrexone-for-weight-loss
#17
(no author information available yet)
No abstract text is available yet for this article.
November 10, 2014: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/25258511/naltrexone-sustained-release-bupropion-sustained-release-for-the-management-of-obesity-review-of-the-data-to-date
#18
REVIEW
Assumpta Caixàs, Lara Albert, Ismael Capel, Mercedes Rigla
Obesity is an emerging disease worldwide. Changes in living habits, especially with increased consumption of high-calorie foods and decreased levels of physical activity, lead to an energy imbalance that brings weight gain. Overweight and obesity are major risk factors for several chronic diseases (including cardiovascular diseases, diabetes, and cancer), reduce quality of life, and are associated with higher mortality. For all these reasons, it is of the utmost importance that the trend be reversed and obese people enabled to lose weight...
2014: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/24898338/the-effect-of-pulsed-ir-light-on-the-rheological-parameters-of-blood-in-vitro
#19
Honorata Nawrocka-Bogusz, Anna Marcinkowska-Gapińska
In this study we attempted to assess the effect of light of 855 nm wavelength (IR-light) on the rheological parameters of blood in vitro. As an anticoagulant, heparin was used. The source of IR-light was an applicator connected to the special generator--Viofor JPS®. The blood samples were irradiated for 30 min. During the irradiation the energy density was growing at twelve-second intervals starting from 1.06 J/cm2 to 8.46 J/cm2, then the energy density dropped to the initial value; the process was repeated cyclically...
2014: Biorheology
https://www.readbyqxmd.com/read/24078918/analysis-of-the-magnetic-field-influence-on-the-rheological-properties-of-healthy-persons-blood
#20
Anna Marcinkowska-Gapinska, Honorata Nawrocka-Bogusz
The influence of magnetic field on whole blood rheological properties remains a weakly known phenomenon. An in vitro analysis of the magnetic field influence on the rheological properties of healthy persons blood is presented in this work. The study was performed on blood samples taken from 25 healthy nonsmoking persons and included comparative analysis of the results of both the standard rotary method (flow curve measurement) and the oscillatory method known also as the mechanical dynamic analysis, performed before and after exposition of blood samples to magnetic field...
2013: BioMed Research International
keyword
keyword
100659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"